HoldsUp

Thomas Seyfried

Boston College

Thomas Seyfried, PhD, is a professor of biology at Boston College who specializes in the metabolic origins and treatment of cancer. He is the author of "Cancer as a Metabolic Disease" and co-developed the Glucose Ketone Index. His published research focuses on ketogenic metabolic therapy, mitochondrial metabolic theories of cancer, cellular fermentation mechanisms, and repurposed drug combinations for conditions such as glioblastoma.

62 claims checked on air: 16 context 9 contradicted 7 overstated 27 supported 3 unverified

What they said on air

18 citing their own research

0:08:56overstatedvery lowtheir own paperEmily Kaplan and Dr. Seyfried: The oncology field must under

The Glucose Ketone Index can be used as a clinical tool to monitor and manage all major chronic diseases and cancers.

"Our big paper that just came out last week, Frontiers in Science, talks about the glucose ketone index as a tool for managing all the major chronic diseases and cancers." (said at 0:08:56)

The Glucose Ketone Index (GKI) was introduced by Seyfried and colleagues as an experimental metric to track metabolic ketosis and blood glucose in preclinical models and preliminary trials of brain tumors (such as glioblastoma). Claiming that GKI is an established clinical tool to monitor and manage 'all major chronic diseases and cancers' is a substantial overstatement. Systematic reviews show that even in brain tumors, evidence for ketogenic metabolic therapy is limited, heterogeneous, and unproven for survival outcomes, and broad clinical utility across all chronic diseases has not been validated in clinical trials.

0:10:28overstatedvery lowtheir own paperEmily Kaplan and Dr. Seyfried: The oncology field must under

Ketogenic metabolic therapy combined with targeted drugs facilitates drug delivery across the blood-brain barrier for pediatric brain cancers.

"And I think that with the big paper that we had with Purna Mukherjee a couple of weeks ago in Cell Reports Medicine, we've shown how ketogenic metabolic therapy can facilitate drug delivery to manage these different cancers. Brain can—childhood brain cancer, number one killer of little kids. We know how to manage that now effectively without toxicity." (said at 0:10:28)

Evidence for ketogenic diet acting as a metabolic vehicle to enhance drug delivery and therapeutic efficacy for pediatric brain cancers comes entirely from preclinical animal models (juvenile syngeneic mice) and in vitro cell lines, rather than clinical human trials. A recent study in Cell Reports Medicine demonstrated that a ketogenic diet combined with repurposed/targeted drugs (mebendazole and devimistat) enhanced survival and reduced tumor invasion while allowing lower drug dosing in juvenile mouse glioblastoma models, but clinical efficacy in pediatric patients remains unproven.

0:10:47supportedmoderateEmily Kaplan and Dr. Seyfried: The oncology field must under

Brain cancer is the leading cause of disease-related death in children.

"Brain can—childhood brain cancer, number one killer of little kids." (said at 0:10:47)

Epidemiological analyses of pediatric oncology data, including the Global Burden of Disease Study and national cancer registries, confirm that childhood brain and central nervous system (CNS) tumors are the leading cause of cancer- and disease-related mortality in children (surpassing leukemia following advances in hematologic cancer therapies).

0:11:18needs contextvery lowtheir own paperEmily Kaplan and Dr. Seyfried: The oncology field must under

Cancer cells drive dysregulated growth through the fermentation of glutamine via substrate-level phosphorylation in the mitochondrial matrix.

"one of the mechanisms to drive dysregulated cell growth is the fermentation of glutamine. That's why you have to go back before you can talk about mebendazole, fenbendazole, and some of these others. You have to know how we made the second major discovery after Otto Warburg, which was the fermentation of an amino acid in the matrix of the mitochondria through substrate-level phosphorylation." (said at 0:11:18)

The claim accurately describes the mitochondrial metabolic theory of cancer articulated by Thomas Seyfried and colleagues, which posits that cancer cells utilize glutamine-driven mitochondrial substrate-level phosphorylation (specifically via the succinate-CoA ligase step in the TCA cycle within the mitochondrial matrix) as a fermentation mechanism to generate ATP and drive dysregulated growth when oxidative phosphorylation is impaired. However, the evidence base for this concept consists primarily of theoretical narrative reviews and in vitro preclinical experiments in glioma cell lines, rather than definitive evidence across broad human clinical malignancies.

0:11:59supportedmoderateEmily Kaplan and Dr. Seyfried: The oncology field must under

Parasites utilize glutamine fermentation and mitochondrial substrate-level phosphorylation to survive in host tissues.

"But it turns out that parasites use the same pathway to live in tissues. So I learned that they use the same inside the matrix of the mitochondria. They're fermenting. The parasites are fermenting using glutamine and mitochondrial substrate-level phosphorylation." (said at 0:11:59)

Parasitic protozoans and helminths commonly utilize fermentation pathways and mitochondrial substrate-level phosphorylation (mSLP)—such as via succinyl-CoA synthetase (SCS) coupled with acetate:succinate CoA-transferase (ASCT)—to generate ATP and survive within host tissue environments, particularly under nutrient- or oxygen-restricted conditions.

0:12:45contradictedlowtheir own paperEmily Kaplan and Dr. Seyfried: The oncology field must under

Mebendazole targets the glutaminolysis pathway to kill parasites and can kill cancer cells via the same metabolic target.

"We just published the mechanism in Purna's paper. We clearly showed that mebendazole targets the glutaminolysis pathway to kill the parasite, and also because the cancer cell is using the same pathway in part, then you—then you manage the cancers the same way." (said at 0:12:45)

Mebendazole's primary and well-established mechanism of action against parasites is the selective binding to helminth β-tubulin and disruption of microtubule polymerization, not targeting the glutaminolysis pathway. Similarly, in oncology research, its primary antitumor mechanism is described as the inhibition of tubulin polymerization alongside anti-angiogenic and signaling pathway alterations. While isolated preclinical studies have noted downstream metabolic effects such as glycolysis and glutaminolysis inhibition in specific glioma cell lines, glutaminolysis is not the recognized parasitic target or the primary antitumor mechanism.

0:20:05supportedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

The longest living human being ever documented lived to age 122.

"Even the healthiest person in the world, the—the longest-living person, human being, ever recorded was Madame Calment from France, 122. And she's the only human being that ever lived that long." (said at 0:20:05)

Demographic validation studies confirm that Jeanne Calment is the longest-living documented human being, having lived to the validated age of 122 years and 164 days before her death in 1997.

0:21:32supportedlowEmily Kaplan and Dr. Seyfried: The oncology field must under

Pediatric brain tumors are metabolically dependent on both glucose and glutamine for growth.

"And these tumors are also dependent on the sugar glucose and the amino acid glutamine. And I don't see any—any intervention in the pediatric neuro-oncology field of simultaneously targeting glucose and glutamine like we did in our preclinical study published in Cell Reports Medicine" (said at 0:21:32)

Preclinical metabolic profiling, animal xenograft studies, and patient imaging in pediatric brain tumors—including medulloblastoma and diffuse intrinsic pontine glioma (DIPG)—demonstrate a strong metabolic dependence on both glucose (glycolysis/TCA cycle) and glutamine (glutaminolysis) to sustain energy production, macromolecular biosynthesis, epigenetic reprogramming, and tumor progression. Because evidence derives primarily from preclinical cell and animal models alongside translational imaging studies, the certainty is graded as low.

0:22:03unverifiedvery lowEmily Kaplan and Dr. Seyfried: The oncology field must under

Nutritional ketosis enhances drug delivery across the blood-brain barrier, allowing for lower therapeutic dosages.

"Once you bring the body into a state of nutritional ketosis, you can use very low doses of these drugs. They pass right through the blood-brain barrier. So that's why Purna Mukherjee said it's a facilitator. It's the way to get these drugs—a vehicle for getting drugs through the blood-brain barrier, which we've established through mass spec analysis, and you don't have to use as much dosage." (said at 0:22:03)

No published clinical or preclinical studies verify the claim that nutritional ketosis broadly enhances drug delivery across the blood-brain barrier to allow lower therapeutic dosages. Preclinical studies on ketogenic diets have primarily investigated neurovascular integrity, monocarboxylate transporters, and clearance mechanisms (such as P-glycoprotein and LRP1-mediated efflux of amyloid-beta), but not enhanced brain penetration of general pharmaceuticals.

0:29:20supportedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

Ketogenic metabolic therapy has been used clinically in children for decades to manage epilepsy.

"And then, of course, when you realize that ketogenic metabolic therapy has been used in little children for managing epilepsy for decades, and then you have kids with brain cancer right down the hall that should be using the same kind of thing." (said at 0:29:20)

Ketogenic diet therapy (ketogenic metabolic therapy) has been used clinically as an established non-pharmacological treatment for drug-resistant epilepsy in pediatric patients since the 1920s (a century of clinical use). Extensive systematic reviews and randomized controlled trials confirm its established role and efficacy in reducing seizure frequency in children with refractory epilepsy.

0:30:32supportedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

Dr. Russell Wilder introduced the ketogenic diet in 1921 to manage epileptic seizures after observing that water fasting reduced seizures in children.

"But that goes back to Wilder, 1921, when he first used ketogenic metabolic therapy to manage epileptic seizures because he found that children or people, when they just drank water for a few days, the seizures would subside. But you can't do that for very long. So he developed then this high-fat diet that would create an internal metabolic environment similar to water-only fasting." (said at 0:30:32)

Historical medical literature confirms that Dr. Russell Wilder introduced the ketogenic diet at the Mayo Clinic in 1921. He proposed the diet as a way to mimic the biochemical effects of fasting (ketonemia/ketogenesis), which had previously been observed to reduce epileptic seizures.

0:31:28supportedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

A clinical trial led by Helen Cross demonstrated that ketogenic metabolic therapy significantly reduces epileptic seizures in children.

"So Helen Cross from England and a group from Johns Hopkins, Beth Zupec-Kania, and all these folks that I know set up a clinical trial. And clearly, without any ambiguity, the ketogenic metabolic therapy was powerful in reducing epileptic seizures for children." (said at 0:31:28)

A landmark randomized controlled trial led by J. Helen Cross and colleagues (Neal et al., 2008, The Lancet Neurology) evaluated 145 children aged 2-16 years with treatment-resistant epilepsy. The trial demonstrated that after 3 months, seizure frequency was significantly lower in children assigned to a ketogenic diet compared to controls (mean percentage of baseline seizures: 62.0% vs. 136.9%, p < 0.0001), with 38% of children on the diet achieving a >50% seizure reduction compared with 6% of controls.

0:33:00contradictedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

About 50% of cancer deaths are caused by treatment-related complications rather than the cancer itself.

"And about 50% of people die from—they call it die from the complications of cancer. What's that? That's dying from the drugs that you use to treat the patient." (said at 0:33:00)

The claim that approximately 50% of cancer deaths are caused by treatment complications rather than cancer itself is contradicted by extensive epidemiological data and oncology clinical trials. The vast majority of cancer deaths are attributable to progressive underlying malignancy, metastatic disease, and tumor-associated organ failure. In population-based studies of metastatic cancer mortality, over 80% of deaths are directly due to the diagnosed cancer. Even in intensive treatment settings (such as pediatric oncology), treatment-related mortality accounts for roughly one-quarter of deaths, and in standard adult oncology regimens, treatment-related toxic death rates typically remain well below 5-10%.

0:37:00supportedmoderateEmily Kaplan and Dr. Seyfried: The oncology field must under

Cancer cachexia involves the mobilization of skeletal muscle proteins for gluconeogenesis and direct tumor utilization of glutamine.

"And cachexia, which is the action of the tumor on the muscles, they will mobilize proteins out of the muscles and create sugar from gluconeogenesis and using glutamine directly." (said at 0:37:00)

Cancer cachexia is established to involve systemic host hypercatabolism, characterized by skeletal muscle proteolysis that releases free amino acids into circulation to fuel hepatic gluconeogenesis and meet the metabolic demands of the growing tumor (such as glutaminolysis and energy production).

0:38:25supportedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

All mitochondria in the human body are derived exclusively from the maternal egg.

"And when I look at mitochondria, all of the mitochondria in our body were derived from the egg, the mother's egg." (said at 0:38:25)

Human mitochondrial DNA (mtDNA) is inherited exclusively through the maternal lineage. Although sperm introduce mitochondria into the oocyte during fertilization, paternal mitochondria are devoid of intact mtDNA and lack the transcription factor TFAM required for mtDNA maintenance, and paternal mitochondrial structures are targeted for elimination via mitophagy and ubiquitin-proteasome pathways. While isolated reports proposed biparental transmission, large-scale genomic analyses showed these were artifacts caused by nuclear insertions of mitochondrial DNA (mega-NUMTs) rather than paternal mitochondrial transmission.

0:48:05unverifiedvery lowEmily Kaplan and Dr. Seyfried: The oncology field must under

The compound IP6 was too toxic when tested in clinical settings and animal models for pancreatic cancer, but became non-toxic and therapeutically synergistic when combined with metabolic therapy.

"And one of the drugs, IP6, was used in the clinic for pancreatic cancer and it was a bust. It was too toxic. We gave it to the mice and it was too toxic. But when we gave it to them in metabolic therapy, it was not toxic and it was super powerful." (said at 0:48:05)

No published clinical trials or animal studies were identified demonstrating that inositol hexaphosphate (IP6 / phytic acid) was too toxic in pancreatic cancer models, nor that combining it with metabolic therapy eliminated toxicity. IP6 is a naturally occurring polyphosphorylated carbohydrate found in high-fiber foods and dietary supplements, and existing preclinical research in pancreatic cancer cell lines has examined it as a non-toxic dietary agent rather than a toxic compound requiring metabolic rescue.

0:51:00contradictedlowEmily Kaplan and Dr. Seyfried: The oncology field must under

Brain radiation increases extracellular glucose and glutamine levels, elevating blood sugar and upregulating cortisol in patients.

"They nuke people's brains freeing up massive amounts of glucose and glutamine and then are surprised... You irradiate a person, the blood sugar goes through the roof. Your whole body goes into a survival mode. Cortisol upregulated." (said at 0:51:00)

Clinical microdialysis studies in patients receiving cranial radiation for high-grade gliomas do not support the claim. Studies evaluating brain tumor extracellular fluid during radiotherapy found that extracellular glucose and glucose metabolites did not significantly increase. Furthermore, serum metabolome analysis found that circulating glutamine and other metabolites decreased rather than causing elevated blood sugar, and there is no evidence establishing that brain radiation induces systemic hyperglycemia via increased extracellular glucose and glutamine or cortisol upregulation.

0:52:00needs contextvery lowtheir own paperEmily Kaplan and Dr. Seyfried: The oncology field must under

In a Greek clinical trial of 18 glioblastoma patients receiving standard radiation, those who followed a calorie-restricted Mediterranean diet had significantly improved survival and a higher rate of reaching the three-year mark.

"Even in even in our Greek trial where we had 18 patients, those individual, they were all nuked. And I hate to say it, but that's what they do... But those individuals that did a a calorie-restricted Mediterranean diet lived significantly longer. More of them made the three-year mark than the ones who didn't take the Mediterranean diet." (said at 0:52:00)

The speaker appears to be referring to a 2024 Greek clinical study of 18 patients with glioblastoma (PMID 40041752), but misidentifies the intervention. The study tested dietary ketogenic metabolic therapy (a ketogenic diet), not a calorie-restricted Mediterranean diet. In that prospective cohort of 18 patients, 6 patients adhered to the ketogenic diet for >6 months and exhibited a significantly higher 3-year survival rate compared to the 12 non-adherent patients (66.7% vs. 8.3%, p = 0.0114). However, the evidence certainty is very low due to the tiny sample size, lack of randomization, and inherent selection/adherence bias (e.g., immortal time and healthier-patient bias in those able to adhere). Furthermore, a separate cohort study specifically assessing Mediterranean-like diets in glioblastoma found no survival benefit (PMID 40690185).

1:05:24contradictedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

All major cancer tumors ferment energy due to mitochondrial dysfunction, and no tumor grows uncontrollably without relying on a fermentation mechanism.

"We know that all major cancers that we have looked at, we have never found a tumor that's not fermenting as the result of mitochondrial dysfunction. We have never found that. I I Thomas Seyfried has a thousand reward for anybody to show us a tumor that's growing out of control not using a fermentation mechanism and we can't find any." (said at 1:05:24)

The claim reflects Otto Warburg's original 1920s hypothesis that cancer is fundamentally caused by irreversible mitochondrial dysfunction forcing cells into fermentation (aerobic glycolysis). Modern oncology and metabolic biochemistry have extensively refuted this universal generalization. Contemporary evidence demonstrates that mitochondria remain fully functional and intact in the vast majority of cancers. Many tumors maintain active mitochondrial oxidative phosphorylation (OXPHOS), some are predominantly OXPHOS-dependent, and metabolic plasticity allows tumors to utilize both pathways rather than relying exclusively on fermentation.

1:05:58needs contextmoderateEmily Kaplan and Dr. Seyfried: The oncology field must under

The majority of dementia cases stem from mitochondrial dysfunction rather than rare inherited genetic mutations.

"the majority of dementia is the result of mitochondrial dysfunction. I mean, there are we all have rare inherited mutations that will be, uh, risk factors for a very few number of people. Most people with dementia are from from abusing mitochondria in one way or another." (said at 1:05:58)

The speaker correctly notes that rare, deterministic inherited genetic mutations account for only a small minority of dementia cases (e.g., autosomal dominant mutations in APP, PSEN1, and PSEN2 account for roughly 1% to 5% of Alzheimer's disease cases, with ~95% classified as sporadic). However, framing the majority of cases as definitively 'stemming from' mitochondrial dysfunction simplifies a complex, multifactorial etiology. While mitochondrial impairment and oxidative stress are recognized as prominent early pathophysiological features—and form the basis of the 'mitochondrial cascade hypothesis'—sporadic dementia arises from a complex combination of advanced aging, polygenic susceptibility (such as APOE alleles and dozens of GWAS risk loci), vascular changes, neuroinflammation, and proteopathy rather than a proven sole origin in mitochondrial failure.

1:06:15needs contextlowEmily Kaplan and Dr. Seyfried: The oncology field must under

Paleolithic humans and traditional populations rarely experienced chronic diseases or cancer, dying primarily from infant mortality, infections, and injuries.

"You have to go back and look at our paleolithic ancestors uh or people who live on the planet today according to the traditional ways. They rarely if ever have any chronic diseases or cancer. Uh most of it is injuries and infections. People always say, well, they didn't live long enough. Paleolithic man 300,000 200,000 years ago didn't live long. What are you talking Infant mortality was what was largely killing those people. Infections and injuries. They weren't dying from type 2 diabetes." (said at 1:06:15)

Studies of modern traditional subsistence populations (such as the Tsimane forager-horticulturalists) demonstrate remarkably low rates of chronic cardiometabolic conditions (such as coronary atherosclerosis, hypertension, and type 2 diabetes), with infectious diseases and inflammatory burden predominating. However, extending these findings to all Paleolithic humans and claims of extremely rare cancer requires nuance, as paleopathological detection of cancer is limited by fossil preservation, smaller older-age demographic fractions, and diagnostic constraints.

1:09:55overstatedlowEmily Kaplan and Dr. Seyfried: The oncology field must under

Following the adoption of Western diets, 50% of Inuit populations suffer from cancer, dementia, and diabetes.

"I know that because I gave a lecture at Thunder Bay Medical School in Canada that serves the Inuit populations and they used to be some of the healthiest people on the planet and now they're some of the most unhealthy people. 50% have cancer and dementia and all kinds of diabetes. They never ate highly processed carbs and you give it to them now as wards of the state and the next thing you know they're all they have every kind of a chronic disease you can possibly imagine." (said at 1:09:55)

Epidemiological studies and systematic reviews demonstrate that dietary transition away from traditional diets toward Western, refined-carbohydrate diets has led to increased rates of non-communicable chronic diseases (including obesity, diabetes, and cardiovascular disease) among Inuit and other indigenous populations. However, the specific claim that 50% of Inuit populations suffer from cancer, dementia, and diabetes is a significant exaggeration. Cross-sectional epidemiological data from Canadian Arctic Inuit/Inuvialuit communities show that roughly 20% of adults report any chronic disease, with age-adjusted prevalence rates of approximately 9% for diabetes and 6% for cancer.

1:12:03contradictedhighEmily Kaplan and Dr. Seyfried: The oncology field must under

Omega-3 polyunsaturated fatty acids from fish oils lower triglycerides, whereas omega-6 polyunsaturated fatty acids are pro-inflammatory.

"So omega-6 versus omega-3s because the fish oils are polyunsaturated fatty acids and they're extremely healthy for you because we've seen triglycerides lowered. We did some big studies on this. But the omega-6 polyunsaturated fatty acids are pro-inflammatory." (said at 1:12:03)

While the first half of the claim is well-established—omega-3 fatty acids from fish oils reliably lower circulating triglyceride levels—the claim that omega-6 polyunsaturated fatty acids (PUFAs) are pro-inflammatory is contradicted by clinical evidence. Multiple systematic reviews and meta-analyses of randomized controlled trials demonstrate that dietary intake of omega-6 fatty acids (such as linoleic acid and arachidonic acid) does not increase systemic inflammatory markers (including CRP, TNF-alpha, and IL-6) in humans. The notion that omega-6 PUFAs promote inflammation is a mechanistic hypothesis that has not been supported by clinical intervention trials.

1:12:20supportedlowEmily Kaplan and Dr. Seyfried: The oncology field must under

Burning ketone bodies significantly reduces the cellular production of reactive oxygen species.

"Also uh when you burn ketones, you reduce reactive oxygen species. That's one of the that's why they call it a superfuel. you don't produce reactive ROS, reactive oxygen species when you're burning ketones." (said at 1:12:20)

Preclinical and in vitro studies demonstrate that the metabolism of ketone bodies (notably beta-hydroxybutyrate) attenuates cellular and mitochondrial reactive oxygen species (ROS) production while enhancing antioxidant defenses (such as glutathione). However, this evidence is primarily established in cellular models and animal tissues rather than direct in vivo human outcome measurements, warranting a low certainty rating.

1:15:45unverifiedvery lowEmily Kaplan and Dr. Seyfried: The oncology field must under

Feeding mice an ad libitum ketogenic diet containing non-sugar sweeteners causes insulin resistance, high blood glucose, and accelerated tumor progression in brain and colon cancer models.

"This new one that just came out on colon cancer in the mice where they ate tubs of lard and the tumors grew faster. We showed it in brain cancer, too. When you give the animals all the lard they want, all the sweet fat, blood sugar stays... Well, they put in KetoCal was a they put a sweetener in there. It was a a sugar substitute not raising blood sugar but making the food taste a little more palatable. The mice chowed down like there was no tomorrow. And we gave it to them ad libitum without any calorie restriction. Oh my god, the tumors were blowing out going through their ears and the blood sugar was high. They created insulin insensitivity eating a ketogenic diet unlimited amounts with a sweetener in it" (said at 1:15:45)

A systematic search across PubMed and Europe PMC did not identify any published studies demonstrating that feeding mice an ad libitum ketogenic diet formulated with non-sugar sweeteners causes insulin resistance, elevated blood glucose, and accelerated tumor progression across brain and colon cancer models. While studies (such as PMID 17313687) have compared calorie-restricted versus unrestricted commercial ketogenic formulas (e.g., KetoCal) in mouse brain tumor models, they focused on caloric restriction and metabolic fuel availability rather than attributing adverse metabolic and oncologic outcomes specifically to non-sugar sweeteners.

1:20:42supportedmoderateEmily Kaplan and Dr. Seyfried: The oncology field must under

Individuals with inborn carnitine deficiency may need carnitine supplementation to achieve a low Glucose Ketone Index.

"And don't forget carnitine deficiency which is an inborn error of metabolism. Most people never even recognize it. May have to have carnitine supplementations to get down into the low GKI." (said at 1:20:42)

Carnitine is an essential cofactor for the transport of long-chain fatty acids across the inner mitochondrial membrane via carnitine palmitoyltransferases for beta-oxidation and subsequent hepatic ketogenesis. Primary (inborn) carnitine deficiency impairs fatty acid oxidation, classically resulting in hypoketotic hypoglycemia during fasting or metabolic stress. Because achieving a low Glucose Ketone Index (GKI) requires substantial ketone body production relative to blood glucose, individuals with inborn defects in carnitine transport or metabolism require L-carnitine supplementation to restore mitochondrial fatty acid transport and enable ketogenesis.

0:00:45supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Approximately 1,700 people die from cancer each day in the United States, which equals about 70 deaths per hour.

"There's 1,700 people a day in this country dying from cancer. That's 70 an hour. And it gets worse every single year." (said at 0:00:45)

According to the American Cancer Society's annual reports on US cancer statistics based on National Center for Health Statistics (NCHS) mortality data, approximately 610,000 to 618,000 cancer deaths occur annually in the United States (e.g., 609,820 projected in 2023; 611,720 in 2024; and 618,120 in 2025). Dividing these figures across 365 days yields approximately 1,670 to 1,694 deaths per day (~1,700/day), which corresponds to roughly 70 cancer deaths per hour.

0:01:00needs contextmoderateLeading Cancer Researcher: They’re Ignoring My Research

Cancer is the leading cause of death in domestic dogs, whereas wolves in the wild rarely develop cancer.

"And then if you look at the domestic dog, cancer is the number one killer of the domestic dog. But wolves in the wild rarely have cancer." (said at 0:01:00)

Cancer is well-established in veterinary epidemiology as a leading cause of death in domestic dogs, particularly in older dogs and specific breeds where neoplasia accounts for a substantial proportion of overall mortality. In wild wolves (Canis lupus), clinically overt cancer is rarely reported or identified as a primary cause of death; however, this disparity is largely driven by life-history and survival differences: wild wolves typically die at much younger ages from intraspecific aggression, human persecution, starvation, trauma, and infectious diseases before reaching the advanced ages at which cancer predominantly manifests.

0:04:01needs contexthighLeading Cancer Researcher: They’re Ignoring My Research

All mitochondria present in a developing embryo originate from the mother's cytoplasm at conception.

"So, you have to realize that at the time of conception all of the mitochondria for the developing embryo are in the cytoplasm from the mother." (said at 0:04:01)

Mitochondrial inheritance in mammals is strictly maternal, and the functional mitochondria in a developing embryo derive from the maternal oocyte. However, at the exact moment of conception, the fertilizing sperm does introduce a small number of paternal mitochondria (approx. 50–100) into the oocyte cytoplasm. These paternal mitochondria are rapidly recognized, ubiquitinated, and degraded during early cleavage stages via post-fertilization mitophagy (mediated by pathways including PARKIN, MUL1, and SQSTM1/p62), leaving exclusively maternal mitochondria to populate the embryo.

0:09:12supportedvery lowLeading Cancer Researcher: They’re Ignoring My Research

Intermittent hypoxia from conditions such as sleep apnea generates reactive oxygen species that damage mitochondrial membranes.

"Intermittent hypoxia, like people who have sleep apnea, they stop breathing for 30 seconds or more in that general and then that creates ROS, R-O-S. And that's what carcinogens do, ROS. These are called reactive oxygen species. They damage those delicate membranes." (said at 0:09:12)

Extensive in vitro and animal models of obstructive sleep apnea (OSA) and chronic intermittent hypoxia (CIH) demonstrate that CIH cycles induce excessive reactive oxygen species (ROS) and lipid peroxidation, leading to loss of mitochondrial membrane potential, structural disruption of mitochondrial membranes, and impaired mitochondrial bioenergetics. Because this specific biological mechanism is established primarily in cellular and animal experimental models, certainty is graded as very low under GRADE.

0:11:14supportedlowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

When mitochondrial oxidative phosphorylation becomes impaired, mitochondria can generate ATP from glutamine via substrate-level phosphorylation in the matrix.

"When this organelle becomes impaired, these ancient pathways of energy through fermentation arise. Okay, they try to replace the lost energy from the efficiency of this organelle. That space starts throwing out ATP from glutamine. It's another fermentation fuel." (said at 0:11:14)

Preclinical and mechanistic studies demonstrate that when oxidative phosphorylation (OxPhos) is compromised (e.g., due to hypoxia, respiratory chain inhibition, or mitochondrial defects), cells can generate ATP in the mitochondrial matrix via mitochondrial substrate-level phosphorylation (mSLP). This process occurs through glutaminolysis fueling the tricarboxylic acid cycle, specifically via the succinate-CoA ligase (succinyl-CoA synthetase) step. Evidence is derived from in vitro cellular assays and metabolic biochemistry models, which limits certainty to low under GRADE.

0:12:44supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Cyanide causes lethal toxicity by binding to proteins required for cellular oxygen utilization in energy production.

"Cyanide is a perfect example of this. You take a mouse or a rat or a person and you drink Kool-Aid, the cyanide-laced Kool-Aid, you die. Because what happens is that cyanide binds to the protein that's going to use oxygen for energy. And the whole system shuts down." (said at 0:12:44)

Cyanide's canonical mechanism of acute lethal toxicity is the inhibition of cytochrome c oxidase (Complex IV of the mitochondrial electron transport chain). Binding to this terminal respiratory enzyme prevents mitochondrial oxygen utilization and halts aerobic ATP synthesis (oxidative phosphorylation), leading to cellular histotoxic hypoxia and metabolic failure.

0:17:38supportedmoderateLeading Cancer Researcher: They’re Ignoring My Research

During cardiac arrest, the bloodstream rapidly accumulates fermentation products including lactic acid and succinic acid.

"When people have heart attacks, they stop breathing. The heart seizes. Okay, the bloodstream immediately fills with these fermentation waste products, which are lactic acid, and the other one, which we now know is succinic acid." (said at 0:17:38)

During whole-body ischemia such as cardiac arrest, lack of oxygen halts aerobic respiration and forces cells into anaerobic metabolism. This leads to the rapid generation and accumulation of lactic acid (via anaerobic glycolysis) and succinic acid (succinate, via reversal of succinate dehydrogenase and the malate-aspartate shuttle). Extensive metabolomic studies establish that succinate and lactate accumulation is a universal metabolic signature of ischemia across multiple tissues and organ systems.

0:20:05contradictedhighLeading Cancer Researcher: They’re Ignoring My Research

Cancer cells take in oxygen primarily to generate reactive oxygen species rather than to produce substantial amounts of ATP.

"We showed the cancer cell takes in oxygen, but it's not making energy through ATP in any great amount. It's using it for ROS, these radicals that further damage and cause the DNA mutations that everybody is chasing." (said at 0:20:05)

The claim that cancer cells take in oxygen primarily to produce reactive oxygen species (ROS) rather than ATP contradicts fundamental cellular bioenergetics and modern cancer metabolism research. In eukaryotic and cancer cells alike, the vast majority of consumed oxygen (>95-99%) is reduced to water by complex IV (cytochrome c oxidase) in the mitochondrial electron transport chain to support oxidative phosphorylation (OXPHOS) and ATP synthesis. Only a small fraction (typically 0.1-2%) of consumed oxygen results in premature electron leakage and ROS generation. Furthermore, extensive research demonstrates that mitochondria in most cancer cells remain functional and actively produce substantial amounts of ATP via OXPHOS alongside glycolysis.

0:21:57overstatedvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

All cancer cells examined under electron microscopy exhibit structural defects in their mitochondria, such as missing or deformed cristae.

"We've discussed cancer cells, all of them that we have ever looked at have defects in the number, structure, and function of that organelle. Okay? I published that big paper where I spent over a year of my time going through the early electron microscopy literature... I looked at these electron micrographs of mitochondria in various cancers and they're all damaged." (said at 0:21:57)

While abnormal mitochondrial ultrastructure (such as altered cristae density, swelling, or membrane abnormalities) is frequently observed in various tumor cell lines and tissues and forms a key premise of metabolic theories of cancer, claiming that *all* cancer cells universally exhibit structural mitochondrial defects under electron microscopy is an overstatement. Cancer cells demonstrate substantial heterogeneity in mitochondrial ultrastructure, dynamics, and oxidative phosphorylation capacity across different cancer types and differentiation states.

0:23:15supportedmoderateLeading Cancer Researcher: They’re Ignoring My Research

Mitochondria-associated membranes in contact with the endoplasmic reticulum are structurally abnormal in cancer cells under electron microscopy.

"There is intimate contacts between some of the other membranes, mitochondrial-associated membranes we see. And they're also abnormal when you look at them under the electron microscope." (said at 0:23:15)

Ultrastructural studies using transmission electron microscopy (TEM) have repeatedly demonstrated structural alterations in mitochondria-associated endoplasmic reticulum membranes (MAMs / ER-mitochondria contact sites) in cancer cells. Under electron microscopy, cancer cells exhibit remodeling, stabilization, or disruption/reduction of ER-mitochondria contacts depending on the tumor type and therapeutic resistance state (e.g., markedly reduced ER-mitochondria connectivity identified by EM in multidrug-resistant tumor cells, or altered contact architecture modulating apoptosis and calcium/lipid transfer).

0:25:05supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Glutamine is the most abundant amino acid circulating in the human bloodstream.

"And the amino acid glutamine... Our bodies are loaded with glutamine. That's the most abundant amino acid in our bloodstream." (said at 0:25:05)

Glutamine is universally recognized in human physiology and biochemistry as the most abundant free amino acid in human blood plasma, typically comprising approximately 20% of the total circulating free amino acid pool.

0:28:49supportedmoderateLeading Cancer Researcher: They’re Ignoring My Research

Inflammatory cytokines damage the ability of mitochondria to generate energy through oxidative phosphorylation efficiently.

"So we have shown that inflammation produces the cytokines when you have an inflammatory heat in inflammation. They damage the ability of this organelle to make energy efficiently." (said at 0:28:49)

A broad body of mechanistic, in vitro, animal, and translational human disease studies demonstrates that pro-inflammatory cytokines (such as TNF-α, IL-6, and IL-1β) directly and indirectly impair mitochondrial oxidative phosphorylation (OXPHOS) and cellular bioenergetics. Exposure to pro-inflammatory cytokines causes downregulation of OXPHOS complex genes, disrupts mitochondrial membrane potential and ultrastructure, elevates reactive oxygen species (ROS), and shifts cellular metabolism away from efficient mitochondrial respiration toward glycolysis.

0:31:28needs contextmoderateLeading Cancer Researcher: They’re Ignoring My Research

Wolves in the wild rarely have cancer, whereas cancer is the number one cause of death in domestic dogs.

"Wolves in the wild rarely have cancer. The domestic dog, cancer is the number one killer of the domestic dog." (said at 0:31:28)

Cancer is indeed recognized as a leading cause of death in domestic companion dogs, with studies documenting that neoplastic disease accounts for a large fraction of deaths (and the single most common disease category in many older dog populations and specific breeds). However, stating that wild wolves 'rarely have cancer' while domestic dogs do requires important context. In the wild, wolves rarely die of cancer primarily because wild wolves experience high mortality at younger ages from anthropogenic causes (hunting, trapping, vehicle collisions), intraspecific conflict/trauma, starvation, and infectious diseases before reaching the advanced ages at which cancer typically manifests. In contrast, captive wolves that reach older ages do develop neoplasms, and domestic dogs live substantially longer in protected environments with veterinary care, allowing age-related diseases like cancer to emerge as a primary cause of mortality.

0:33:14supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Inherited cancer-predisposing genetic mutations such as BRCA1 and Li-Fraumeni syndrome (TP53) are not 100% penetrant.

"none of these mutations are 100% penetrant, meaning that they're secondary risk factors... There's no gene mutation that's 100% penetrant. You have that gene, you're going to 100% get cancer. Most of them are what they call incompletely penetrant." (said at 0:33:14)

Large-scale epidemiological studies and meta-analyses confirm that high-penetrance cancer predisposition genes like BRCA1 and TP53 (Li-Fraumeni syndrome) exhibit incomplete (non-100%) penetrance. For BRCA1 mutation carriers, cumulative cancer risk by age 70 is approximately 57% for breast cancer and 40% for ovarian cancer. For TP53 pathogenic variant carriers, although cancer risk is extremely high, cumulative penetrance remains incomplete, with estimates by age 50 reaching approximately 92.4% in females and 59.7% in males.

0:33:45needs contextlowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Cancer-predisposing genetic mutations disturb the efficiency of mitochondrial oxidative phosphorylation.

"Bob went back and he looked at what every one of those gene mutations in some way disturbs the efficiency of oxidative phosphorylation in that organelle... all of them damage the efficiency of energy through this organelle." (said at 0:33:45)

Certain hereditary cancer-predisposing mutations directly affect mitochondrial respiration. Notably, germline mutations in succinate dehydrogenase subunits (SDHA, SDHB, SDHC, SDHD—components of mitochondrial Complex II / TCA cycle) impair mitochondrial function and predispose to familial pheochromocytomas and paragangliomas. However, the claim that cancer-predisposing genetic mutations generally or universally act by disrupting mitochondrial oxidative phosphorylation represents a broad metabolic hypothesis (e.g., the Warburg/mitochondrial theory of oncogenesis) rather than a universal feature of all known cancer predisposition genes.

0:34:10supportedmoderateLeading Cancer Researcher: They’re Ignoring My Research

Oncogenic viruses like hepatitis and human papillomavirus produce products that damage mitochondrial oxidative phosphorylation or replicate in mitochondria, driving compensatory fermentation.

"The viruses like hepatoma and papilloma, their products will go in here and damage it, or they will replicate inside this organelle, screwing up the efficiency, causing a compensatory fermentation" (said at 0:34:10)

Mechanistic and molecular studies show that oncogenic viruses, including human papillomavirus (HPV) and hepatitis viruses (HBV/HCV), encode viral products that disrupt mitochondrial oxidative phosphorylation (OXPHOS), target mitochondrial DNA, and shift cellular metabolism toward glycolysis and lactate production (compensatory fermentation/the Warburg effect).

0:39:20supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Ketone bodies are water-soluble breakdown products of long-chain fatty acids that can replace glucose as energy for the brain, muscles, and most cells except erythrocytes.

"outcome these little soluble ketone bodies. They're breakdown products of long-chain fatty acids. They can replace sugar for the brain, for the muscles, for most other cells in the body except erythrocytes. But they can replace the energy of glucose." (said at 0:39:20)

Ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone) are water-soluble molecules produced by hepatic beta-oxidation of fatty acids during low carbohydrate availability. They cross the blood-brain barrier and serve as an alternative metabolic fuel to glucose for peripheral tissues including the brain, heart, and skeletal muscle. Mature erythrocytes lack mitochondria and cannot perform oxidative phosphorylation or ketolysis, remaining obligately dependent on anaerobic glycolysis of glucose.

0:40:26supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Stress elevates corticosteroid hormones, which in turn raises blood sugar levels and contributes to systemic inflammation.

"Stress elevates corticosteroids. When you're under stress, you get into a fight, get into an argument, or you're stressed out by a business deal going bad, whatever, corticosteroids elevate blood sugar, contributing to systemic inflammation." (said at 0:40:26)

Extensive physiological and clinical evidence supports the claim. Stress activates the hypothalamic-pituitary-adrenal (HPA) axis to release glucocorticoids (such as cortisol). Glucocorticoids stimulate hepatic gluconeogenesis and decrease peripheral glucose uptake in skeletal muscle and adipose tissue, leading to elevated blood glucose levels. Additionally, while acute glucocorticoids are anti-inflammatory, prolonged stress and sustained glucocorticoid exposure induce glucocorticoid receptor resistance, impairing the normal negative feedback on the immune response and promoting systemic inflammation.

0:41:20needs contextlowLeading Cancer Researcher: They’re Ignoring My Research

Neurons in Parkinson's disease die when mitochondria are damaged because they cannot compensate using fermentation, making neuronal cancer very rare.

"for Parkinson's disease, when that organelle gets damaged, the cells of the substantia die. They are incapable of compensating with fermentation, so they up and die. Cancer is very rare in neurons of the brain. The glial cells of the brain form these brain tumors mostly." (said at 0:41:20)

The claim combines established neurobiology with a misleading causal link. Dopaminergic neurons in Parkinson's disease are indeed highly susceptible to mitochondrial dysfunction and energy failure, and mature neurons rely primarily on oxidative phosphorylation with limited ability to upregulate glycolysis/fermentation to sustain their massive energy demands. However, the primary reason mature neuronal cancers (such as adult brain tumors of neuronal origin) are exceedingly rare is that mature neurons are terminally differentiated, post-mitotic cells that do not undergo cell division, rather than solely because they cannot switch to fermentation.

0:46:40contradictedmoderateLeading Cancer Researcher: They’re Ignoring My Research

Cancer cells cannot effectively burn ketone bodies or fatty acids for energy due to structural and functional defects in their mitochondria.

"they can't burn ketones because you need a very efficient mitochondria to burn ketones for energy... If the organelle is damaged, they can't use the ketones. They can't burn fatty acids or ketones, which stores lipid droplets." (said at 0:46:40)

Extensive preclinical research in oncology contradicts the generalized claim that cancer cells cannot effectively oxidize fatty acids or ketone bodies due to mitochondrial defects. While Otto Warburg originally postulated irreversible mitochondrial injury in cancer, contemporary evidence demonstrates that many tumor types retain functional mitochondria and actively utilize fatty acid oxidation (FAO) and ketone bodies (such as beta-hydroxybutyrate) for aerobic respiration, ATP generation, and tumor growth. For instance, malignant glioma and triple-negative breast cancer cells exhibit high bioenergetic reliance on mitochondrial fatty acid oxidation, and breast cancer models demonstrate that ketone bodies can directly fuel tumor growth via oxidative mitochondrial metabolism.

0:54:55needs contextmoderateLeading Cancer Researcher: They’re Ignoring My Research

Diabetic ketoacidosis typically presents with blood ketone concentrations of 15 to 20 millimolar, whereas nutritional ketosis is much lower.

"Ketoacidosis is like when you have ketone levels of 15 to 20 millimolar. Are you kidding me? What is your 0.4? That's called nutritional ketosis." (said at 0:54:55)

The core physiological distinction is accurate: nutritional ketosis generates substantially lower blood ketone levels (typically 0.5 to 3.0 mmol/L, with studies on very-low-carbohydrate diets demonstrating mean beta-hydroxybutyrate levels around 1.2 mmol/L) compared to diabetic ketoacidosis (DKA). However, claiming that DKA 'typically presents' with 15 to 20 mM needs qualification: while extreme, uncontrolled ketoacidosis can reach double-digit millimolar concentrations, clinical diagnostic criteria and typical clinical presentations for DKA are established at beta-hydroxybutyrate concentrations of ≥3.0 to ≥3.8 mmol/L.

0:57:00supportedvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Mebendazole exerts therapeutic anticancer effects by targeting both glucose and glutamine metabolic pathways.

"I've looked at one and that's mebendazole. Okay? How did I come to that realization? People knew that mebendazole had some therapeutic benefit about cancer, but they don't believe until they show the mechanism. That paper shows the mechanism. It targets glucose and glutamine." (said at 0:57:00)

Preclinical evidence supports that mebendazole (MBZ) exerts anticancer effects in part by inhibiting both glucose metabolism (glycolysis) and glutamine metabolism (glutaminolysis), as demonstrated in in vitro and syngeneic mouse glioma models. However, evidence remains limited to preclinical experimental systems.

0:57:15needs contextlowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Cancer cell growth is primarily driven by fermentation of two main fuels: glucose and the amino acid glutamine.

"the two fuels driving the dysregulated growth of the tumor... it's getting the glucose in the cytoplasm from the sugar uh and making and it's fermenting that and then also the the amino acid glutamine comes in." (said at 0:57:15)

Glucose and glutamine are widely recognized as two central metabolic fuels for many proliferating cancer cells (via aerobic glycolysis/the Warburg effect and glutaminolysis). The specific framing that cancer growth is universally and primarily driven by 'fermentation' (substrate-level phosphorylation) of glucose and glutamine reflects a specific metabolic theory of cancer promoted by certain researchers (e.g., Seyfried and colleagues). Broader consensus in cancer biology emphasizes significant metabolic heterogeneity: many cancers maintain functional mitochondrial oxidative phosphorylation (OXPHOS) and utilize other substrates (such as fatty acids and lactate) depending on tumor type and microenvironment.

0:59:20overstatedlowLeading Cancer Researcher: They’re Ignoring My Research

Nutritional ketosis enhances drug delivery and therapeutic efficacy in tumor cells, permitting lower doses of chemotherapy drugs like cisplatin and carboplatin.

"the ketogenic state of nutritional ketosis facilitates the delivery of drugs to the tumor cell. It actually makes You can use lower doses of drugs and you and and you get bigger effect. The therapeutic benefit increases with lower dosing." (said at 0:59:20)

Preclinical models (in vitro and animal xenografts) and preliminary early-phase clinical trials indicate that a ketogenic diet can induce metabolic stress, alter redox balance, and potentially sensitize some tumor types to cytotoxic chemotherapies like cisplatin. However, the claim that nutritional ketosis enhances drug delivery and permits lower doses of chemotherapy drugs (such as cisplatin or carboplatin) in clinical oncology is an overstatement. Clinical trials evaluate ketogenic diets as an adjunct to standard full-dose chemotherapy regimens, not as a validated means for dose de-escalation or enhanced drug delivery.

1:02:50needs contextlowLeading Cancer Researcher: They’re Ignoring My Research

Fermentation waste products, specifically lactic acid and succinic acid, shield tumor cells from the cytotoxic effects of chemotherapy and radiation.

"What protects the tumor cell from chemo and radiation is the waste products of fermentation. The lactic acid and the succinic acid that are dumped out of this raging beast prevent these other therapies from working." (said at 1:02:50)

Preclinical and mechanistic literature supports the concept that glycolytic reprogramming and lactate (lactic acid) accumulation in the tumor microenvironment contribute to tumor cell survival, radioresistance, and chemoresistance. However, describing these metabolites purely as protective 'waste products' is a simplification of complex metabolic and oncogenic signaling pathways, and evidence demonstrating resistance mechanisms stems largely from in vitro and preclinical animal models rather than direct clinical trial endpoints.

1:04:25supportedmoderateLeading Cancer Researcher: They’re Ignoring My Research

Cancer cachexia involves the tumor actively mobilizing glutamine out of host skeletal muscle, driving muscle breakdown to fuel tumor metabolism.

"Cachexia is the ability of the tumor cell to mobilize energy out of the muscles. It's taking the glutamine out of your muscles and feeding This is one of the two fuels that's driving the beast is glutamine. Where are they getting the glutamine from? They're getting the glutamine not only from the bloodstream, but they dissolve your muscles as a as part of that, part of that process." (said at 1:04:25)

Preclinical and metabolic studies support the concept that tumors function as avid consumers of glutamine ('glutamine trap'), leading to depleted intramuscular glutamine pools and increased skeletal muscle proteolysis and efflux of amino acids (notably glutamine) to support tumor metabolic demands and host immune responses.

1:08:04needs contextvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Nuclear transfer experiments show that transferring a tumor nucleus into enucleated normal cytoplasm yields normal growth, while transferring a normal nucleus into tumor cytoplasm yields dysregulated cancerous growth.

"You take that nucleus and put it into into a enucleated normal cell... There's no dysregulated... Then you take the nucleus of the normal cell and put it into the cytoplasm of a tumor cell and you get dysregulated cell growth." (said at 1:08:04)

Nuclear transplantation and transmitochondrial cybrid experiments have shown that introducing a tumor nucleus into normal enucleated cytoplasm (such as an oocyte or normal cytoplast) can suppress tumorigenicity and permit early embryonic development or differentiated tissue formation, whereas transferring tumor cytoplasm/mitochondria to cells with normal nuclei can promote tumorigenic phenotypes. However, the claim requires qualification: while tumor nuclei can direct early development (e.g., blastocysts or tadpoles), most cloned embryos arrest during development or develop abnormalities, and mainstream oncology attributes these effects to epigenetic reprogramming by oocyte cytoplasm and mitochondrial signaling rather than proving that cancer is solely driven by cytoplasmic defects.

1:12:56contradictedhighLeading Cancer Researcher: They’re Ignoring My Research

There has been no major advance in managing glioblastoma in 100 years.

"There has been no major advance in managing glioblastoma in 100 years." (said at 1:12:56)

The claim that there has been no major advance in managing glioblastoma in 100 years is contradicted by clinical evidence. Prior to modern interventions, untreated glioblastoma carried a median survival of approximately 3 months. Over the past several decades, the development of modern surgical cytoreduction, adjuvant radiotherapy, and the landmark 2005 Stupp protocol (adding concurrent and adjuvant temozolomide chemotherapy to radiotherapy) established a new standard of care, extending median overall survival to approximately 14.6–15 months. While prognosis remains poor and progress has been incremental compared to other malignancies, key therapeutic advances have substantially extended survival beyond historical baseline levels over the past century.

1:27:18overstatedvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Hyperbaric oxygen selectively kills cancer cells by generating oxidative stress in cells that have impaired oxidative phosphorylation.

"hyperbaric oxygen will create oxidative stress in cells that do not have efficient oxidative phosphorylation. Uh cancer cells. Cancer cells. So you can kill cancer cells by oxidative stress by irradiating or poisoning them, or you can put a patient into a nutritional ketosis and then put them in hyperbaric oxygen and the cancer cells are selectively killed." (said at 1:27:18)

The claim represents a proposed metabolic cancer therapy hypothesis (often championed in preclinical research by Thomas Seyfried, Dominic D'Agostino, and colleagues), which suggests that tumors with defective mitochondrial respiration/oxidative phosphorylation are selectively vulnerable to hyperbaric oxygen therapy (HBOT)-induced reactive oxygen species (ROS). However, claiming that HBOT definitively and selectively kills cancer cells in this manner is overstated: evidence supporting this mechanism is restricted to in vitro and preclinical mouse models (e.g., VM-M3 metastatic cancer models), and robust clinical trial data showing selective tumor eradication in humans via HBOT-induced oxidative stress are lacking.

1:30:26overstatedvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Every chemical linked to carcinogenesis and dysregulated cell growth chronically damages mitochondrial oxidative phosphorylation.

"And every one of the chemicals that we have looked at that has been linked to oncology, dysregulated cell growth, all damage the oxidative phosphorylation chronically." (said at 1:30:26)

The assertion that *every* chemical linked to carcinogenesis acts by chronically damaging mitochondrial oxidative phosphorylation reflects the Mitochondrial Metabolic Theory of cancer (originally based on Otto Warburg's hypothesis and championed by Thomas Seyfried), but is an overstatement. Established toxicology and cancer biology demonstrate diverse mechanisms of chemical carcinogenesis, including direct genotoxicity (DNA adduct formation, alkylation), epigenetic modifications, receptor-mediated pathways, and immune dysregulation. While some carcinogens can cause mitochondrial impairment or reactive oxygen species generation, universal chronic damage to oxidative phosphorylation is not demonstrated or accepted for all chemical carcinogens.

1:31:46contradictedmoderatetheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Pure stem cell tumors cannot metastasize on their own.

"Stem cell tumors cannot metastasize. How do I know? Because I had stem cell tumors diagnosed as stem cell tumors with stem cell markers. I've grown them. They grow very angry. They get a lot of blood vessels, but they can't spread." (said at 1:31:46)

Standard cancer biology and oncology literature establish that cancer stem cells (CSCs) possess self-renewal capacity, multilineage differentiation, and tumor-initiating potential, and are primary drivers of invasion, progression, and distant metastasis. The assertion that 'pure stem cell tumors cannot metastasize on their own' reflects a non-consensus hypothesis (primarily advanced by Thomas Seyfried and colleagues based on specific murine brain tumor models such as VM-NM1), which posits that metastatic capability arises from macrophage fusion or myeloid traits rather than stem cells alone. Established evidence contradicts the broad absolute claim that stem-like tumor cells lack metastatic capacity.

1:32:10needs contextlowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Metastatic cancer cells are formed when immune cells fuse with tumor stem cells to create migratory macrophage-tumor cell hybrids.

"How do you get spreading tumor cells in your body? The immune system comes in, recognizes that as an unhealed wound, and then fuses with the stem cells. And then you have these hybrid cells. They are programmed to move around your body. So, they are a macrophage tumor cell hybrid." (said at 1:32:10)

Macrophage-tumor cell fusion is a well-documented and actively investigated biological mechanism in cancer biology (originally popularized in modern oncology by Thomas Seyfried and John Pawelek, among others). In vitro, animal models, and patient samples show that fusion between macrophages (or other myeloid immune cells) and neoplastic cells generates hybrid cells (often termed tumor hybrid cells or circulating hybrid cells) that acquire macrophage-like motility, invasiveness, and immune evasion. However, presenting this as the sole or definitive origin of all metastatic cancer cells is an oversimplification: mainstream oncology recognizes cell fusion as one of several contributing mechanisms alongside epithelial-mesenchymal transition (EMT), clonal evolution, and tumor microenvironment remodeling.

1:32:30needs contextlowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Metastatic macrophage-tumor hybrid cancer cells rely primarily on glutamine and glucose for energy.

"So, and they're very hard to kill. But, we found they're remarkably sensitive. They're glutamine-driven. So, we know they're glutamine-driven, and they need the glucose, and that's why That's why metabolic therapy done the right way can nail nail those metastatic cancer cells." (said at 1:32:30)

The claim reflects a specific metabolic theory of cancer metastasis (advanced primarily by Thomas Seyfried and colleagues), which posits that metastatic cancer cells—hypothesized to arise in part from macrophage-tumor cell fusion hybridization—rely heavily on fermentable fuels, specifically glucose and glutamine (via glycolysis and mitochondrial substrate-level phosphorylation). While research indicates that glucose and glutamine are major metabolic fuels for tumor cells and myeloid-derived lineages, the broader macrophage-tumor cell fusion hybrid hypothesis and the absolute dependency of metastatic cells on only these two substrates remain theoretical frameworks and preclinical models rather than universally established clinical consensus.

1:32:55supportedvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

The press-pulse therapeutic strategy continuously restricts glucose and pulses glutamine inhibition to target metastatic cancer cells.

"Don't forget, my colleagues and I, Dom D'Agostino and Joe Maroon, we built the press-pulse therapeutic strategy. I mentioned that on your previous show. That's the way you you you press down the glucose of the tumor, and then you pulse to kill the glutamine, which will which will uh target the metastatic cancer cells" (said at 1:32:55)

The 'press-pulse' therapeutic strategy proposed by Thomas Seyfried and colleagues specifically outlines using continuous, chronic stress (the 'press', typically via calorie-restricted ketogenic diets to continuously restrict glucose) coupled with acute intermittent stressors (the 'pulse', such as acute glutamine inhibition or oxidative stress) to target the metabolic vulnerabilities of cancer cells. The claim accurately describes this theoretical metabolic framework. However, the evidence base for this specific combined strategy in cancer remains preclinical/theoretical, warranting a very low GRADE certainty regarding established clinical efficacy.

1:36:39needs contextvery lowtheir own paperLeading Cancer Researcher: They’re Ignoring My Research

Studies reporting that cancer cells can use fatty acids and ketone bodies for energy contain confounding glucose and glutamine in their culture media.

"My students are on the on the alert for any paper that comes out that says cancer— "Oh, cancer cells can burn fatty acids and ketone bodies." Oh, really? Let's go back through and dissect out their control experiments, and you find that in every case there was always some glucose and glutamine in the media making it look like the fatty acids." (said at 1:36:39)

Standard in vitro cell culture formulations (e.g., standard DMEM, RPMI) contain supraphysiological concentrations of glucose (5.5–25 mM) and glutamine (2–4 mM). Proponents of the mitochondrial metabolic theory of cancer, such as Thomas Seyfried, argue that reports of cancer cells surviving on fatty acids or ketone bodies are confounded because standard media provide glucose and glutamine for substrate-level phosphorylation (fermentation). However, the broader cancer metabolism literature contains extensive evidence using isotope tracing, dialyzed serum, and substrate-depleted media showing that specific cancer subtypes can perform fatty acid oxidation and utilize ketone bodies under defined conditions. The claim accurately reflects an ongoing methodological critique in cancer metabolic research, but it presents a contested theoretical viewpoint as an established consensus.

1:39:51supportedhighLeading Cancer Researcher: They’re Ignoring My Research

Carnitine deficiency impairs the transport of fatty acids required to synthesize ketone bodies.

"Oh, the other thing, too, is you got to be cuz some people have carnitine deficiencies. Carnitine prevents fatty acids from being made into ketone bodies. So So So carnitine supplementation can help them." (said at 1:39:51)

Carnitine is an essential cofactor of the carnitine palmitoyltransferase (CPT) shuttle, which is responsible for transporting long-chain fatty acids across the inner mitochondrial membrane into the mitochondrial matrix. In the liver, mitochondrial beta-oxidation of these fatty acids produces acetyl-CoA, the direct substrate for ketogenesis. Primary or severe carnitine deficiency impairs this transport mechanism, characteristically presenting clinically with hypoketotic hypoglycemia during fasting.

Fact-checked episodes

Publications